CONMED Corporation: Q2 2012 Form 10-Q Summary
Business context and reporting period
CONMED is a medical technology company serving minimally invasive surgery and monitoring markets, including arthroscopy, powered surgical instruments, electrosurgery, cardiac monitoring, endosurgery and endoscopic technologies. The filing covers the three and six months ended June 30, 2012. International sales represented approximately 50.8% of quarterly sales and 50.7% of year-to-date sales.
Financial performance and liquidity
| Metric | Three months ended June 30 | Six months ended June 30 |
|---|---|---|
| Net sales | $189.7 million, up 3.5% | $384.0 million, up 4.7% |
| Gross profit / margin | $99.7 million / 52.6% | $200.6 million / 52.2% |
| Income from operations | $17.1 million / 9.0% margin | $34.1 million / 8.9% margin |
| Net income | $10.3 million | $20.3 million |
| Diluted EPS | $0.36 | $0.71 |
| Operating cash flow | Not separately provided | $33.3 million |
At June 30, 2012, cash and cash equivalents were $16.2 million, compared with $26.0 million at December 31, 2011. Net working capital was $202.2 million. Total debt was approximately $168.0 million, consisting of $22.5 million of current debt and $145.4 million of long-term debt. The company had $137.0 million drawn on its $250.0 million revolving facility and approximately $103.2 million of available revolver capacity, with about $9.8 million reserved for letters of credit.
Year-to-date investing cash outflows were $75.7 million, including $64.1 million related to the Musculoskeletal Tissue Foundation agreement and $11.6 million of capital expenditures. Financing cash flow was $32.9 million, reflecting $57.0 million of revolver borrowings, $32.1 million of debt repayments, $7.9 million of employee-plan share issuance proceeds and $4.3 million of dividends. Capital expenditures are expected to approximate $20.0 million for 2012.
Material changes versus the prior comparable period
- Quarterly sales increased $6.5 million, while six-month sales increased $17.3 million. Growth was led by Arthroscopy, including the MTF distribution agreement, and Endoscopic Technologies.
- Single-use product sales increased 7.5% in the quarter and 8.3% year to date, while capital equipment sales declined 10.7% and 7.6%, respectively, reflecting hospital capital-purchasing constraints.
- Gross margin improved from 49.9% to 52.6% for the quarter and from 51.0% to 52.2% year to date, primarily due to the MTF agreement and product mix.
- Operating margin was broadly stable quarterly but declined year to date, as higher selling expenses, restructuring, legal and distributor-acquisition costs offset gross-margin improvement.
- Net income increased from $8.7 million to $10.3 million for the quarter and from $17.7 million to $20.3 million year to date. Lower interest expense and a lower effective tax rate contributed to the improvement.
- The effective tax rate declined to 33.6% from 37.5% quarterly and to 34.8% from 37.4% year to date, partly due to foreign earnings and tax benefits from examinations and tax filings.
Guidance, outlook, commentary, risks and unusual items
- Management expects 2012 restructuring costs of approximately $11.5 million to $12.5 million, including production transfers to Mexico, Finland operations consolidation and administrative restructuring. No material restructuring accrual had been recorded at June 30.
- The MTF agreement involved a $63.0 million upfront payment and up to $84.0 million of contingent payments over four years. The full $84.0 million was accrued because management believed the supply targets were probable; the arrangement had a $149.4 million gross carrying amount and $3.0 million of accumulated amortization at June 30.
- Management expects to fund the remaining MTF payments through cash on hand and available revolver capacity and believes liquidity is adequate for operations, debt service, capital expenditures and planned activities.
- The remaining $21.5 million term-loan principal was due September 30, 2012, and management expected to refinance it with the revolving facility. The company was in compliance with its debt covenants at June 30.
- Other expense included $1.2 million of administrative consolidation costs and $0.5 million of legal costs in the quarter. Year-to-date other expense also included $0.7 million related to acquiring a Nordic distributor and $1.6 million related to a former-distributor contractual dispute. The dispute was resolved and no further expense was expected.
- Key risks include hospital capital-budget constraints, economic weakness in Europe and other markets, foreign exchange volatility, competition, product development and acceptance, regulatory actions or recalls, product liability, patent litigation, availability of allograft tissue, acquisition integration and the achievement of restructuring savings.
- The company maintains $25 million of product-liability insurance per incident and in the annual aggregate, but warns that claims could exceed coverage or that coverage may become unavailable or more expensive.
Most important facts for investors to verify
- Whether single-use product growth and the MTF relationship can offset continued weakness in capital equipment sales.
- The timing and funding of the remaining $84.0 million in contingent MTF payments and the effect of related amortization on sales.
- Whether expected 2012 restructuring costs remain within the $11.5 million to $12.5 million estimate and produce the anticipated savings.
- Post-quarter-end refinancing or repayment of the $21.5 million term-loan maturity and continued compliance with debt covenants.
- Progress in improving the loss-making Patient Care segment and the declining-margin Endoscopic Technologies segment.
- Exposure to foreign exchange movements, regulatory matters, product liability, litigation and potential impairment of the company’s $234.8 million of goodwill and $191.7 million of other intangible assets.